Sutro Biopharma, Inc.
STRO
$39.69
-$1.22-2.98%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 65.18% | -34.36% | -38.31% | -56.88% | -59.64% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 65.18% | -34.36% | -38.31% | -56.88% | -59.64% |
| Cost of Revenue | -33.97% | -14.46% | 2.17% | 24.69% | 39.69% |
| Gross Profit | 66.35% | -28.92% | -142.16% | -311.34% | -611.77% |
| SG&A Expenses | -15.34% | -26.39% | -17.82% | -18.04% | -22.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -30.97% | -16.77% | -1.98% | 14.77% | 23.66% |
| Operating Income | 55.99% | -5.01% | -56.00% | -121.30% | -167.09% |
| Income Before Tax | 15.07% | -98.29% | -93.23% | -149.95% | -154.06% |
| Income Tax Expenses | -104.23% | -85.22% | -86.76% | -86.72% | -87.01% |
| Earnings from Continuing Operations | 15.99% | -74.88% | -67.70% | -113.31% | -112.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.99% | -74.88% | -67.70% | -113.31% | -112.99% |
| EBIT | 55.99% | -5.01% | -56.00% | -121.30% | -167.09% |
| EBITDA | 57.78% | -4.90% | -59.51% | -129.62% | -180.41% |
| EPS Basic | 24.53% | -58.64% | -35.73% | -56.43% | -66.54% |
| Normalized Basic EPS | 51.83% | -3.28% | -26.36% | -56.09% | -103.46% |
| EPS Diluted | 24.53% | -58.64% | -35.73% | -56.43% | -66.54% |
| Normalized Diluted EPS | 51.83% | -3.28% | -26.36% | -56.09% | -103.46% |
| Average Basic Shares Outstanding | 9.86% | 18.03% | 26.54% | 36.02% | 28.57% |
| Average Diluted Shares Outstanding | 9.86% | 18.03% | 26.54% | 36.02% | 28.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |